Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) has been given an average rating of “Hold” by the seven research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $42.40.
Several analysts have recently issued reports on PAHC shares. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Finally, Citigroup began coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $62.00 price objective on the stock.
Get Our Latest Stock Analysis on Phibro Animal Health
Phibro Animal Health Stock Performance
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, research analysts predict that Phibro Animal Health will post 3.06 earnings per share for the current year.
Phibro Animal Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.4%. The ex-dividend date is Wednesday, June 3rd. Phibro Animal Health’s payout ratio is currently 20.60%.
Insider Activity
In other news, CEO Jack Bendheim sold 4,528 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the transaction, the chief executive officer owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 110,128 shares of company stock valued at $5,846,828 over the last ninety days. 50.13% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares during the period. State Street Corp raised its holdings in shares of Phibro Animal Health by 5.4% during the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after buying an additional 48,243 shares during the period. Millennium Management LLC lifted its position in Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after acquiring an additional 626,492 shares in the last quarter. Geode Capital Management LLC lifted its position in Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Phibro Animal Health by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company’s stock worth $28,086,000 after acquiring an additional 15,517 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Featured Articles
- Five stocks we like better than Phibro Animal Health
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
